Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Optimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s Ataxia
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track ...
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation
Fast-track status will allow Solid Biosciences to have more frequent meetings with the FDA throughout the treatment-development process and, potentially, get the product to patients faster than would ...
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the ...
Pharmabiz2d
Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia
Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia: Bala Cynwyd, Pennsylvania Saturday, January 25, 2025, 15: ...
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment
Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical ...
Pharmabiz4d
Solid Biosciences’ AAV-based gene therapy candidate, SGT-212 for Friedreich’s ataxia receives US FDA fast track designation
Charlestown, Massachusetts Thursday, January 23, 2025, 15:00 Hrs [IST] ...
Larimar Therapeutics’ (LRMR) Buy Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $15.00 target ...
West Lothian dad to run Edinburgh Half Marathon for girl with debilitating condition
Eight-year-old Ella-Rose Kennedy has Friedreich ataxia – a consider which causes damage to the nervous system and cerebellum, ...
24/7 Wall St. on MSN6d
Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street Expert
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...